Skip to main content
Caplight Logo









Oxeia Biopharmaceuticals

Oxeia Biopharmaceuticals

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://www.oxeiabiopharma.com/

Last Round

Crowdfunding

Jan 7, 2026

Est. Valuation

$50M

Total Funding Raised

$1.98M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Oxeia Biopharmaceuticals is a clinical-stage biotechnology company developing OXE103, a therapeutic for the treatment of concussion (mild traumatic brain injury).

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

concussion treatmentOXE-103concussion drugmild traumatic brain injurymTBIpost-concussion syndromesynthetic ghrelinclinical stage biotechneuroprotective drugPhase 2 clinical trialneurotherapeuticsfirst-in-class therapybrain injury therapyghrelin analogblood-brain barrieraxonal injury

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Oxeia Biopharmaceuticals Comparables

Compare Oxeia Biopharmaceuticals with similar companies based on industry and business-model similarity.

Oxeia Biopharmaceuticals comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Astrocyte Pharmaceuticals Inc.
83%
Oragenics, Inc.
78%
Odyssey Health, Inc.
77%

Oxeia Biopharmaceuticals Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
CrowdfundingJan 7, 2026
Convertible DebtNov 18, 2025
Convertible DebtOct 2, 2023
SeedApr 2, 2015

Key People

Founding team and executive leadership

Michael S. Wyand

CEO

Executive Team

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 16, 2026

    Monthly visitors increased 82% MoM.

  • Nov 9, 2025

    Monthly visitors increased 123% MoM, reaching 3.9K.

Oxeia Biopharmaceuticals Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Oxeia Biopharmaceuticals Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Oxeia Biopharmaceuticals's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range9
Year Founded2014
Last FundingJan 7, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?